We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App

Automated Immunohematology Approaches Can Resolve Transplant Incompatibility

By LabMedica International staff writers
Posted on 13 Feb 2024
Print article
Image: The IH-500 System is setting new standards immunohematology testing (Photo courtesy of Bio-Rad)
Image: The IH-500 System is setting new standards immunohematology testing (Photo courtesy of Bio-Rad)

The persistent global shortage of donor organs has made the availability of ABO-compatible options a rarity for many hospitals, clinicians, and patients requiring organ transplants. Despite this, advancements in desensitization therapies have made ABO-incompatible organ transplants not only possible but also as successful as compatible transplants. For instance, it has become common for patients with blood group O to receive organs from donors with type A2 blood, a subgroup of the A blood type that expresses fewer antigens. In such cases, the recipient's plasma can be treated using an immune-adsorption column to reduce the anti-A antibody concentration. Alternatively, when this method is not available, plasmapheresis can be utilized to exchange plasma and reduce the titer of anti-A. The reduction in antibody production can also be achieved through standard immunosuppressants and monoclonal antibodies like rituximab.

The titration of relevant ABO blood group antibodies is crucial in managing potentially incompatible organ transplants. The results from titrations help determine the likely success of a transplant procedure with the appropriate immunosuppressive treatment. Additionally, titrations are useful for monitoring antibody production post-transplant and assessing the risk of antibody-mediated rejection later on. Despite its clinical importance, many hospital labs do not routinely perform titration due to its labor-intensive nature, the high skill level required, and the difficulty in interpreting results. Manual titration also suffers from inherent imprecision due to variations in dilution preparation, dilution medium, red blood cell phenotype and the reaction reading which is difficult to standardize.

This issue is further exacerbated by a decrease in new immunohematologists entering the profession, leading to staffing shortages. This, coupled with increased workloads and financial constraints, makes it harder for hospital labs to offer this service and provide timely, definitive results. Consequently, there is a growing need for hematology labs to automate antibody titration to reduce turnaround times and improve result reliability. Automated immunohematology platforms, such as the IH-500 NEXT System from Bio-Rad Laboratories (Hercules, CA, USA), offer a viable solution, enabling local facilities to perform fully automated titrations. The adoption of automation in numerous immunohematology labs has proven successful, allowing them to provide results to doctors within hours on the same day a blood sample is drawn. This quick turnaround is crucial for efficiently allocating donated organs to needy patients and preventing antibody-mediated organ rejection.

Automation also offers greater precision and standardization, as it prevents technical and manual errors. This reduces the need for extensive training and experience, allowing a broader range of staff to perform antibody titrations and analyze the results. This shift can reduce the load on highly skilled specialists, further shortening the time to results. The widespread adoption of automated titration is essential for supporting future transplant services, ensuring that patients receive the critical organ donations they need as soon as possible.

Related Links:
Bio-Rad Immunohematology

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.